| 指標 | 当期 | 前年同期 | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥161.1B | ¥148.1B | +8.7% |
| Operating Income / Operating Profit | ¥51.0B | ¥41.7B | +22.2% |
| Ordinary Income | ¥56.2B | ¥42.8B | +31.4% |
| Net Income / Net Profit | ¥39.0B | ¥29.4B | +32.6% |
| ROE | 6.9% | 5.5% | - |
For the cumulative period of Q2 FY2026, Revenue was ¥161.1B (YoY +¥13.0B +8.7%), Operating Income was ¥51.0B (YoY +¥9.3B +22.2%), Ordinary Income was ¥56.2B (YoY +¥13.4B +31.4%), and Net Income was ¥39.0B (YoY +¥9.6B +32.6%), continuing the trend of revenue and profit growth. Operating margin expanded +3.5pt to 31.6%, and gross margin improved +2.5pt to 66.6%, indicating a marked trend of margin improvement. By segment, Dental drove high growth with Revenue +17.8% YoY and Operating Income +118.3% YoY; Eyeless Needle posted Revenue +5.9% and Operating Income +14.4%; Surgical showed Revenue +3.4% and Operating Income +5.1%, all remaining solid. Non-operating items included foreign exchange gains of ¥5.6B which boosted Ordinary Income, and Net Income achieved double-digit growth of 32.6%. Operating Cash Flow was ¥63.2B (YoY +110.4%), and Free Cash Flow was ¥57.8B, indicating continued robust cash generation.
[Revenue] The increase in Revenue to ¥161.1B (YoY +8.7%) showed mixed results across segments. Dental-related products recorded ¥53.4B (YoY +17.8%), the highest growth rate, and Operating Income rose substantially to ¥10.0B (margin 18.8%), a YoY increase of +118.3%. Eyeless Needle-related products achieved ¥58.8B (+5.9%), accounting for 36.5% of sales mix, and maintained high profitability with Operating Income of ¥23.7B (margin 40.2%). Surgical-related products were ¥48.8B (+3.4%), slightly slower growth, but secured high profitability with Operating Income of ¥17.3B (margin 35.4%). Although regional and product-level disclosures are not provided, a rapid recovery in Dental and stable growth in Eyeless Needle underpinned the company-wide top line.
[Profit & Loss] Cost of goods sold was ¥53.8B (33.4% of Revenue), resulting in Gross Profit of ¥107.2B (Gross Margin 66.6%), an improvement of +2.5pt from 64.1% a year earlier. SG&A was ¥56.3B (SG&A ratio 34.9%), up +5.7% YoY but below the Revenue growth rate of +8.7%, producing positive operating leverage. Operating Income of ¥51.0B (Operating Margin 31.6%) expanded +3.5pt from 28.2% last year, aided by margin improvement in Dental and a favorable mix toward higher-margin segments. Non-operating items included interest income ¥1.5B and foreign exchange gains ¥5.6B, totaling ¥7.9B in non-operating income; after deducting ¥2.7B in non-operating expenses, Ordinary Income was ¥56.2B (Ordinary Income Margin 34.9%), a substantial expansion of +6.0pt from 28.9% a year earlier. Extraordinary items were minor (Extraordinary Gain ¥0.2B, Extraordinary Loss ¥0.0B), yielding Profit Before Tax ¥56.4B; after deducting income taxes of ¥17.4B, Net Income was ¥39.0B (Net Margin 24.2%), up +4.3pt from 19.9% last year. Other Comprehensive Income expanded by a ¥14.6B foreign currency translation adjustment, bringing Comprehensive Income to ¥53.6B. In conclusion, revenue growth, mix improvement, and operating leverage drove the increase in revenue and profit, with foreign exchange effects further amplifying the increase at the Ordinary and Net Income levels.
Dental-related products recorded Revenue ¥53.4B (YoY +17.8%) and Operating Income ¥10.0B (YoY +118.3%), with margin improving substantially to 18.8% from 9.1% a year earlier (+9.7pt). While detailed drivers of the revenue increase are undisclosed, the sizable margin improvement suggests a shift toward higher-value product mix and progress in cost absorption. Eyeless Needle-related products posted Revenue ¥58.8B (+5.9%) and Operating Income ¥23.7B (+14.4%), with margin of 40.2% slightly up from 39.7% last year, maintaining the highest profitability across the company. The stable growth rate and high margins support this segment's strong competitive advantage. Surgical-related products achieved Revenue ¥48.8B (+3.4%) and Operating Income ¥17.3B (+5.1%), with margin 35.4% slightly up from 34.8%, but its growth rate was the slowest among the three segments. Of the company-wide Operating Income ¥51.0B, Eyeless Needle accounted for 46.5%, Surgical 33.9%, and Dental 19.7%, with Dental's contribution to profits expanding rapidly.
[Profitability] Operating Margin of 31.6% improved +3.5pt from 28.2% last year, supported by both Gross Margin 66.6% (prior year 64.1%, +2.5pt) and SG&A ratio 34.9% (prior year 35.9%, -1.0pt). Net Margin expanded to 24.2% (prior year 19.9%, +4.3pt), and Ordinary Income Margin was 34.9% (prior year 28.9%, +6.0pt), which includes the foreign exchange gain contribution of ¥5.6B. ROE improved to 6.9% from 5.5% (+1.4pt), but with an Equity Ratio of 92.2% reflecting a conservative capital structure, financial leverage remained at 1.09x, limiting incremental ROE uplift. [Cash Quality] Operating CF / Net Income was high at 1.62x, supporting high cash quality; accrual ratio was -4.0%, and Operating CF / EBITDA was 1.00x, corroborating solid cash generation. [Investment Efficiency] Total Asset Turnover was low at 0.262x (annualized 0.524x), constrained by accumulated cash and deposits of ¥228.4B (37.1% of total assets) and inventories of ¥65.9B (10.7% of total assets). [Financial Soundness] Equity Ratio 92.2%, Current Ratio 856.7%, D/E ratio 0.09x, Interest Coverage 5,097x indicate an extremely strong financial position with minimal short-term debt risk. Net cash was ¥228.3B (Cash & Deposits ¥228.4B - Interest-bearing Debt ¥0.1B), providing ample financial flexibility.
Operating CF increased significantly to ¥63.2B (prior year ¥30.1B, +110.4%), delivering high-quality cash generation with Operating CF / Net Income ratio of 1.62x against Profit Before Tax ¥56.4B. Operating CF before working capital changes was ¥73.3B; main non-cash items included depreciation ¥12.1B, FX loss adjustment -¥4.6B, and interest/dividend adjustments -¥1.5B. Working capital changes were minor: inventories -¥0.1B, trade receivables -¥0.5B, trade payables -¥0.5B, while a decrease in other current assets of +¥11.9B boosted Operating CF. After tax payments of -¥11.6B, Operating CF finalized at ¥63.2B. Investing CF was -¥5.4B, mainly due to CapEx -¥7.7B, a significant reduction from -¥45.8B in the prior year. Net purchases of investment securities were -¥2.2B offset by sales/redemptions of ¥3.0B, resulting in FCF of ¥57.8B (prior year -¥15.8B). Financing CF was -¥23.0B, primarily dividend payments -¥22.6B and lease liability repayments -¥0.3B. Cash & Deposits increased from ¥184.2B at the beginning of the period to ¥228.4B at period-end, a nominal increase of +¥44.2B; including FX translation adjustment +¥10.3B, the net increase was +¥33.9B. Working capital efficiency shows a lengthening trend with DSO 67 days, DIO 446 days, CCC 499 days; notably, Work-in-Progress of ¥32.9B represents 49.9% of inventories ¥65.9B, suggesting production flow congestion and substantial room for improvement.
Operating Income ¥51.0B versus Ordinary Income ¥56.2B shows a divergence of +¥5.2B, mainly due to foreign exchange gains of ¥5.6B (71% of non-operating income ¥7.9B). Foreign exchange gains are externally driven and highly variable, and are largely one-off in nature. Interest income ¥1.5B reflects stable non-operating income associated with accumulated cash balances; returns from investment partnerships ¥0.1B are immaterial. Details of non-operating expenses ¥2.7B are undisclosed, but interest expense is ¥0.0B and other non-operating expenses amount to ¥0.2B, indicating minimal finance costs. Extraordinary items are negligible (Extraordinary Gain ¥0.2B including ¥0.0B from sale of fixed assets; Extraordinary Loss ¥0.0B including ¥0.0B asset retirement loss), thus having minor impact on Net Income ¥39.0B. Comprehensive Income ¥53.6B equals Net Income ¥39.0B plus FX translation adjustment ¥14.6B, reflecting valuation gains from yen depreciation recognized in equity. Accrual ratio -4.0% indicates good cash realization of profits and high quality of Operating Income. However, the contribution of foreign exchange gains (about 11% of Operating Income) is a variable factor for the full year, so monitoring currency movements is important.
Full Year / FY forecast is Revenue ¥328.0B (YoY +9.4%), Operating Income ¥92.0B (+12.3%), Ordinary Income ¥89.5B (+8.2%). Progress through the Q2 cumulative period is Revenue 49.1% (¥161.1B/¥328.0B), Operating Income 55.4% (¥51.0B/¥92.0B), Ordinary Income 62.8% (¥56.2B/¥89.5B), indicating particularly front-loaded progress on the profit side. The upside in Operating Income is mainly driven by Dental's high growth and mix improvement, while Ordinary Income's upside was significantly supported by foreign exchange gains of ¥5.6B. Forecast EPS is ¥65.48; Q2 cumulative EPS was ¥39.58, representing 60.4% progress. Dividend forecast remains unchanged at annual ¥24 (interim ¥17 already paid), implying an assumed payout ratio of approximately 25%, a healthy level. No revisions to earnings forecasts have been made, but given the front-loaded profit progress, if currency remains stable in H2 and cost increases are contained, there is scope for upward revision. Conversely, currency reversal, re-acceleration of SG&A, or one-off quality/production costs are downside risks.
An interim dividend of ¥17 was paid, resulting in a payout ratio of 42.9% against Q2 cumulative EPS ¥39.58. The full-year dividend forecast ¥24 (interim ¥17 + year-end ¥7 assumed) equates to a payout ratio of 36.7% based on forecast EPS ¥65.48, an appropriate level. With FCF ¥57.8B and dividend payments ¥22.6B, FCF coverage is 2.56x, indicating comfortable dividend sustainability. Given Cash & Deposits ¥228.4B (37% of total assets) and a solid cash position, the risk of dividend reduction is extremely low. No share buybacks were conducted in the period; shareholder returns consist solely of dividends. Details of dividend policy are undisclosed, but the company appears to pursue stable dividends. Medium-term capital allocation will focus on balancing expansion of investment opportunities (CapEx & M&A) and strengthening shareholder returns (dividend increases & buybacks).
Foreign Exchange Risk: Foreign exchange gains of ¥5.6B account for 10.0% of Ordinary Income ¥56.2B; a reversal to a stronger yen could cause significant declines in Ordinary and Net Income. The contribution of FX to Operating Income is approximately 11%, so FX assumption variability could materially affect full-year outcomes.
Working Capital Efficiency Risk: With DSO 67 days, DIO 446 days, CCC 499 days, the lengthening trend—particularly Work-in-Progress ¥32.9B (49.9% of inventories)—suggests production bottlenecks or yield issues. Expansion of working capital constrains capital efficiency and ROE; delays in improvement would increase variability in cash generation.
Underinvestment / Production Capacity Risk: CapEx / Depreciation ratio of 0.64x indicates restrained replacement investment, posing a medium-term challenge to productivity improvements and supply capacity expansion. Construction in progress ¥30.2B (11.7% of tangible fixed assets) shows a pipeline, but timing and effectiveness upon commissioning remain uncertain.
Profitability & Returns
| 指標 | 自社 | 中央値 (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 31.6% | 8.8% (3.0%–11.0%) | +22.9pt |
| Net Margin | 24.2% | 5.4% (1.1%–8.2%) | +18.8pt |
The company’s Operating Margin 31.6% exceeds the manufacturing median 8.8% by +22.9pt, and Net Margin 24.2% outperforms the median 5.4% by +18.8pt. The characteristics of high-value-added medical devices and strong pricing power result in top-tier profitability within the industry.
Growth & Capital Efficiency
| 指標 | 自社 | 中央値 (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 8.7% | 11.7% (-5.4%–28.3%) | -3.0pt |
The company’s Revenue growth rate of 8.7% is -3.0pt below the manufacturing median of 11.7%. The industry shows polarization, with high-growth firms (up to 28.3%) and low-growth firms (down to -5.4%); the company occupies a position of moderate, stable growth.
※Source: Company compilation
Trend improvement in margins and front-loaded progress: Operating Margin 31.6% (YoY +3.5pt), Gross Margin 66.6% (+2.5pt) continue to improve, with full-year Operating Income progress at 55.4% showing front-loading. Dental’s high growth (+17.8%) and margin improvement (+9.7pt), and Eyeless Needle’s maintained high profitability (margin 40.2%) indicate structural strengthening of earnings power. The ¥5.6B foreign exchange gain is transient, but operating-level improvements appear sustainable; with stable FX and controlled costs in H2, there is room for upward revision.
Strong cash generation and capital allocation challenge: Robust cash generation continues with Operating CF ¥63.2B (YoY +110%) and FCF ¥57.8B, and high earnings quality evidenced by Operating CF / Net Income 1.62x and accrual ratio -4.0%. However, accumulated Cash & Deposits ¥228.4B (37% of assets), restrained investment (CapEx / Depreciation 0.64x), and a payout ratio of 36.7% highlight the need to optimize capital allocation—balancing investment expansion, enhanced shareholder returns, and M&A. Improving working capital efficiency (DSO 67 days, DIO 446 days, CCC 499 days) is key to improving capital efficiency and ROE.
This report is an earnings analysis document automatically generated by AI analyzing XBRL earnings release data. It does not constitute a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by the Company based on public financial statements. Investment decisions are your responsibility; please consult a professional advisor as necessary before making investment decisions.